GU Cancers 2022 | Does time from initiation of platinum-based chemotherapy to second-line ICIs affect outcomes in mUC?

Dimitrios Makrakis, MD, University of Washington, Seattle, WA, and Rafee Talukder, MD, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, discuss a recent study looking at whether time from initiation of platinum-based chemotherapy to initiation of second-line immune checkpoint inhibitors affects outcomes for patients with metastatic bladder cancer. When comparing a time of less than 6 months to a time of more than 6 months, there was no significant difference in objective response rate (ORR), overall survival (OS), or progression-free survival (PFS). However, when comparing times of less than 3 months, 3-6 months, and more than 6 months, the data showed that worse OS and PFS was achieved by patients with a time of less than 3 months. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.